Chuecas F, Loredo E, Muñoz B, Alfaro J, Grebe G, Lira P
Departamento y Laboratorio de Hematología-Oncología, Facultad de Medicina, P. Universidad Católica de Chile, Santiago.
Rev Med Chil. 1991 Sep;119(9):984-9.
Eight pts with acute myeloid leukemia were studied to assess coagulation and fibrinolysis disturbances as a cause of hemorrhages associated to thrombopenia. Fibrinogen, products of fibrinogen to fibrin degradation, D-dimer, antithrombin III, protein C, plasminogen and alpha-2 antiplasmin determinations were performed at admission, during and after chemotherapy. All pts were on heparin during induction chemotherapy. Coagulation activation, which increased with the onset of chemotherapy (increases in D-dimer) and a decreasing trend at the end of the antileukemic therapy (normalization of fibrinogen levels) was observed. During the whole observation period alpha-2 antiplasmin levels remained very low. No significant changes were observed in antithrombin III or protein C levels. In conclusion, disseminated intravascular coagulation with associated thrombopenia is an important event in acute leukemia and an increased fibrinolytic activity due to low alpha-2 antiplasmin levels may take part in the genesis of hemorrhage. These data suggest that both heparin administration and the use of antifibrinolytic drugs may have a therapeutic effect.
对8例急性髓系白血病患者进行研究,以评估凝血和纤溶紊乱作为血小板减少相关出血原因的情况。在入院时、化疗期间及化疗后进行纤维蛋白原、纤维蛋白原向纤维蛋白降解产物、D - 二聚体、抗凝血酶III、蛋白C、纤溶酶原和α-2抗纤溶酶的测定。所有患者在诱导化疗期间均使用肝素。观察到随着化疗开始凝血激活增加(D - 二聚体升高),而在抗白血病治疗结束时呈下降趋势(纤维蛋白原水平恢复正常)。在整个观察期内,α-2抗纤溶酶水平一直很低。抗凝血酶III或蛋白C水平未观察到显著变化。总之,伴有血小板减少的弥散性血管内凝血是急性白血病中的一个重要事件,由于α-2抗纤溶酶水平低导致的纤溶活性增加可能参与出血的发生。这些数据表明肝素给药和抗纤溶药物的使用可能具有治疗作用。